700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Michael Phillip Lisanti
Department of Stem Cell Biology and Regenerative Medicine
Thomas Jefferson University,USA
Tel. 215-503-9295, Fax 215-923-1098
Dr. Lisanti has been an active research scientist for over 18 years. He obtained his MD-PhD degrees at Cornell University Medical School. From 1992-97, he was a Fellow at the Whitehead Institute at MIT, affiliated with Dr. Harvey Lodish’s laboratory. His work at Whitehead/MIT was the first to establish the role of caveolae and caveolins in signal transduction. Later, as a Professor at the Albert Einstein College of Medicine, his laboratory was the first to develop caveolin-knock-out mice (for the Cav-1, Cav-2, and Cav-3 gene). Caveolin is a structural protein component of caveolae, invaginations of the plasma membrane found in most cell types. Caveolin acts as a scaffolding protein to concentrate, organize, and functionally regulate signaling molecules within caveolar membranes. The caveolin gene family consists of three members: caveolin-1,-2, and -3.
At the Kimmel Cancer Center at Thomas Jefferson University, Dr. Lisanti’s laboratory is focused on the role of Caveolin-1 (Cav-1) in the pathogenesis of human breast cancer, with a strong emphasis on Cav-1 in signaling, cancer, and stem cell biology. Currently, Dr. Lisanti is a Professor of Cancer Biology and Leader of the Program in Molecular Biology and Genetics of Cancer. He is also a Member of the Executive Steering Committee of the Kimmel Cancer Center.